Skin & hair

The Places Vitiligo Resists the Most

Save

Dermatologists have long noticed that vitiligo doesn't repigment evenly across the body — the face and neck respond fastest, the hands and feet slowest, sometimes not at all. That difference isn't a sign a treatment plan has failed. It's site biology, and understanding it changes what a realistic plan looks like for anyone whose patches are concentrated on the fingers, knuckles, or feet.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why the Hands and Feet Resist Treatment

Vitiligo happens when the immune system destroys melanocytes, the cells that make pigment, leaving depigmented white patches 1. Repigmentation after treatment doesn't come from those destroyed cells recovering — it comes from new melanocytes migrating up from the reservoir that survives lower down in the outer root sheath of hair follicles, then spreading outward across the surface of the patch. That mechanism is why the site of a patch matters as much as which treatment is used.

The skin of the palms, fingertips, and the tops of the feet is thin, and much of it is glabrous — hairless, or very sparsely haired compared to the face, trunk, and limbs. Fewer hair follicles means a smaller reservoir of melanocytes available to repopulate the surface, so even a treatment that is working exactly as intended has less raw material to work with on the hands and feet than it does on the cheek or forearm. Where a vitiligo patch sits predicts how well it will respond about as much as which treatment is chosen.

What the Evidence on Phototherapy and Topical Treatment Shows

Narrowband UVB phototherapy is one of the best-studied vitiligo treatments, and systematic review evidence shows it produces meaningful repigmentation over a course of treatment that typically runs for months rather than weeks, with response continuing to build the longer treatment continues 2. Topical ruxolitinib cream, a newer option, was shown in two phase 3 trials to produce significantly more repigmentation than a vehicle cream over 24 to 52 weeks, particularly on the face 3.

Both of those treatments were studied across patients with vitiligo at many body sites, not hands and feet in isolation, and the pattern dermatologists describe from that broader clinical experience is consistent: response is fastest and most complete on the face and neck, intermediate on the trunk and limbs, and slowest — often incomplete even after a full course — on the hands, feet, and areas directly over bony joints like the knuckles and ankles.

What "Hardest to Treat" Actually Means

Hardest to treat doesn't mean untreatable. It means the honest range of outcomes on the hands and feet is wider and skews toward partial results — patches that lighten, shrink at the edges, or develop scattered flecks of returning pigment rather than filling in solidly the way a facial patch often does. For some people, treatment on acral skin stabilizes the patches without meaningfully repigmenting them, which is still a legitimate goal: stopping a patch from spreading further is a real outcome even when the white skin that's already there doesn't fill back in.

A slow or partial response on the hands and feet is not a sign that treatment isn't working elsewhere, and it isn't a reason to stop. Vitiligo treatment plans are usually built around all of a person's patches together, and a face that's repigmenting well alongside hands that are moving more slowly is a normal, expected pattern rather than a treatment failure.

How Treatment Plans Adjust for Acral Vitiligo

Because response on the hands and feet is slower, a longer trial period before judging a treatment is typically built into the plan — a course that might show visible results on the face by three months may need six months or longer to show any change on the fingers. Dermatologists often combine treatments rather than relying on one, layering a topical option like ruxolitinib cream with narrowband UVB phototherapy, since some evidence suggests combination approaches outperform either alone. Reviewing vitiligo treatment options that work as a whole menu, rather than picking one and stopping there, is part of how a plan gets built around a slow-responding site.

When acral patches remain stable but unresponsive after a substantial trial of medical treatment, the conversation shifts toward what's realistic to expect long-term rather than escalating indefinitely. That's a legitimate point to reach, not a failure of the plan or the person following it.

Setting Expectations Before Starting Treatment

Knowing in advance that the hands and feet are the slowest-responding sites changes how someone experiences the first several months of treatment. Without that context, a person watching their face repigment while their fingers stay unchanged can reasonably read that as the treatment failing, when it's actually the expected pattern playing out. A dermatologist who sets that expectation at the start — this will likely move faster here and slower there — gives a person a more accurate way to judge whether treatment is working than judging every patch by the same timeline.

This is also why a discussion of realistic odds by body site belongs at the start of treatment, not after months of disappointment. What vitiligo treatment can honestly return varies enough by location that a single number for "does treatment work" doesn't capture what someone with hand or foot involvement should actually expect.

When to See a Dermatologist About Acral Patches

Slow response on its own isn't a reason to seek urgent care — it's the expected course, and it's worth discussing at a regular follow-up rather than an emergency visit. What does warrant a prompt look is a change in a hand or foot patch's character rather than its color: a spot on the sole, palm, or under a nail that is darkening rather than lightening, has an irregular or asymmetric border, or is a distinct dark or black area rather than a flat white patch. Those features don't fit the pattern of vitiligo, which is a depigmentation with sharp, even borders, and the hands, feet, and nails are also where acral melanoma most often appears — a separate and serious condition that needs its own evaluation.

A dermatologist familiar with a person's vitiligo pattern is the right person to distinguish a new, unrelated change from the slow, expected course of a stable patch.

Common questions

It's possible but less likely than at other sites — the hands and feet have far fewer hair follicles, which hold the reservoir of pigment cells treatment relies on. Many people see partial improvement or stabilization on the hands and feet even when their treatment is working well overall, and that's a realistic, common outcome rather than a sign the treatment has failed.

Longer than you'd wait to judge a facial patch. Where a face might show visible change by three months, hands and feet often need six months or longer of consistent treatment before any response becomes visible, since the response builds slowly. A dermatologist can help set a realistic checkpoint based on the specific treatment being used.

Repigmentation draws on melanocytes that survive in hair follicles, and the face has a much denser concentration of hair follicles than the palms, fingertips, or the tops of the feet. More follicles means a larger reservoir of cells available to repopulate the surface, which is why facial patches typically respond faster and more completely.

Some evidence suggests combining a topical treatment with phototherapy produces better results than either alone, and dermatologists often layer treatments specifically at slower-responding sites like the hands and feet. Whether combination treatment is worth the added time and cost is a conversation for a dermatologist familiar with how a particular patch has responded so far.

Usually, if it's a flat, evenly depigmented patch with sharp borders. But a new dark or black spot, or a patch with an irregular or changing border on the palm, sole, or under a nail, doesn't fit that pattern and should be evaluated directly rather than assumed to be vitiligo, since those sites are also where acral melanoma most commonly appears.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a Hand or Foot Patch Needs a Direct Look

  • —a spot on the palm, sole, or under a nail that is darkening rather than lightening
  • —a patch with an irregular, asymmetric, or spreading border unlike the rest of the vitiligo
  • —a new dark or black area distinct from the surrounding white patches
  • —a nail-bed streak of pigment that widens or extends into the surrounding skin

This article describes general patterns in how vitiligo responds by body site; it cannot assess any individual patch. A dermatologist examining the skin directly is the only way to confirm a diagnosis or judge how a specific area is responding to treatment.

References

  1. 1.National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024). Vitiligo. NIH / NIAMS. link ✓Definitional basis: vitiligo is a chronic autoimmune disorder in which melanocytes are destroyed, causing depigmented patches, with no cure but treatments that can stabilize and repigment.
  2. 2.Bae JM, Jung HM, Hong BY, et al. (2017). Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatology. link ✓Supports that narrowband UVB phototherapy produces meaningful repigmentation in vitiligo, with response continuing to build over a multi-month course of treatment.
  3. 3.Rosmarin D, Passeron T, Pandya AG, et al. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. doi:10.1056/NEJMoa2118828 ✓Supports that topical ruxolitinib cream produced significantly greater facial and total-body repigmentation than vehicle in the TRuE-V1 and TRuE-V2 trials over 24-52 weeks in nonsegmental vitiligo.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library